Screening, Prevention and Management of Chronic Kidney Disease-Management of Diabetic Kidney Disease Infographic

Management of Diabetic Kidney Disease Infographic

Pdf Summary

This document offers a visual guide to current guidelines for managing Diabetic Kidney Disease (DKD), as endorsed by the American Diabetes Association (ADA) Standards of Care in Diabetes—2023. The content emphasizes the importance of integrating various pharmacological agents to reduce cardiorenal risk and manage chronic kidney disease (CKD) effectively in people with diabetes.<br /><br />Key pharmacological agents include:<br />1. **ACE Inhibitors and ARBs**: These help reduce CKD progression and cardiovascular risk. It is advised not to discontinue them solely due to a 30% increase in serum creatinine unless there is evidence of volume depletion.<br /><br />2. **SGLT2 Inhibitors**: Recommended for patients with Type 2 diabetes with CKD, these inhibitors are presumed beneficial for preserving kidney function and reducing cardiovascular events.<br /><br />3. **NS-MRAs (Nonsteroidal Mineralocorticoid Receptor Antagonists)**: Clinical trials show their effectiveness in individuals with CKD, particularly those with albuminuria who are at risk of cardiovascular issues.<br /><br />4. **GLP-1 Receptor Agonists**: These are suggested for further cardiovascular risk management.<br /><br />Important tips include regular monitoring of serum creatinine and potassium levels when employing ACE inhibitors, ARBs, and MRAs. A targeted reduction of 30% or more in urinary albumin levels is recommended for slowing CKD progression in individuals with urinary albumin levels higher than 300 mg/g.<br /><br />The document emphasizes a comprehensive approach via lifestyle modification and diabetes education along with pharmacological intervention, underlining the strategic "pillars of therapy" developed to minimize the risk of cardiorenal events for patients with diabetic kidney disease.<br /><br />For further information, diabetes.org or the helpline 1-800-DIABETES is provided as resources.

Keywords

Diabetic Kidney Disease

American Diabetes Association

Standards of Care

pharmacological agents

cardiorenal risk

chronic kidney disease

ACE Inhibitors

SGLT2 Inhibitors

GLP-1 Receptor Agonists

lifestyle modification